Simple Summary Hepatocellular carcinoma (HCC) is the most frequent primitive cancer of
the liver, accounting for 90% of all recorded cases. HCC is the third most common cause of …

The increasing set of liver-directed therapies (LDT) have become an integral part of
hepatocellular carcinoma (HCC) treatment. These range from percutaneous ablative …

Simple Summary One of the most important abilities of a tumor is to establish a state of
immunosuppression inside the tumor microenvironment. This is made possible through …

Embolic microspheres or beads used in transarterial chemoembolization are an established
treatment method for hepatocellular carcinoma patients. The occlusion of the tumor-feeding …

Simple Summary Liver functional failure is one of the leading causes of cancer-related
death. Systemic chemotherapy usually offers a modest benefit in terms of disease control …

As the leading cause of cancer‐related death, hepatocellular carcinoma (HCC) threatens
human health and limited treatments are available to cure the disease efficiently and …

AIM: To evaluate vascular endothelial growth factor (VEGF) and tryptase in hepatocellular
cancer (HCC) before and after trans-arterial chemoembolization (TACE). METHODS: VEGF …

Hepatocellular carcinoma (HCC) is the fastest growing malignancy in the United States in
relation to mortality. HCC relies on a complex immunosuppressive network to modify the …

This Special Issue of Cancers, titled “Loco-Regional Arterial Chemotherapies Alone or in
Combination with Systemic Treatments for Primary and Secondary Hepato-Pancreatic …

Objective: At present, several molecular targeted agents (MTAs) combined with transarterial
chemoembolization (TACE) have been employed to treat unresectable hepatocellular …